Genmab Is Too Attractive To Ignore
Genmab's shares are down to very attractive levels and hard to ignore. The company's royalty revenues are expected to exceed $2.5 billion this year and potentially $4 billion at peak, driven primarily by Darzalex and Kesimpta. Despite some setbacks and market concerns, Genmab's long-term growth prospects remain strong, supported by growing Epkinly revenues, expanding clinical pipeline and the acquisition of ProfoundBio.
Genmab A/S (GMAB) Q3 2024 Earnings Conference Call Transcript
Genmab A/S (GMAB) Q3 2024 Earnings Conference Call November 6, 2024 12:00 PM ET Company Participants Jan van de Winkel - CEO Brad Bailey - EVP and Chief Commercial Officer Anthony Pagano - CFO Judith Klimovsky - Chief Development Officer Tahamtan Ahmadi - Chief Medical Officer Conference Call Participants Jonathan Chang - LeeRink Partners Paul Jeng - Guggenheim Securities, LLC Zain Ebrahim - JPMorgan Chase Suzanne van Voorthuizen - Kempen & Co. Xian Deng - UBS Yaron Werber - TD Securities Asthika Goonewardene - Truist Securities Yifeng Liu - HSBC Matthew Phipps - William Blair Alistair Campbell - RBC Capital Markets Vikram Purohit - Morgan Stanley Etzer Darout - BMO Capital Markets Operator Hello, and welcome to Genmab's Financial Results Conference Call for the First Nine Months of 2024. As a reminder, this conference call is being recorded.
Genmab: Looking To Manage My Position Around Q3 Earnings
Genmab's robust pipeline, strategic partnerships, and strong 2023 performance, led by DARZALEX and EPKINLY, bolster my bullish conviction despite ongoing legal disputes with Johnson & Johnson. The company's Q3 earnings on November 6th are crucial, with expectations of $817M in revenue and $0.33 EPS, potentially reversing the recent 20% share price drop. Investors should watch for updates on Genmab's pipeline, OpEx, and DARZALEX royalty trends, as well as the impact of the ProfoundBio acquisition.
Is the Options Market Predicting a Spike in Genmab (GMAB) Stock?
Investors need to pay close attention to Genmab (GMAB) stock based on the movements in the options market lately.
Is Genmab (GMAB) Stock Undervalued Right Now?
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
GMAB or INCY: Which Is the Better Value Stock Right Now?
Investors looking for stocks in the Medical - Biomedical and Genetics sector might want to consider either Genmab A/S Sponsored ADR (GMAB) or Incyte (INCY). But which of these two stocks presents investors with the better value opportunity right now?
Down -14.68% in 4 Weeks, Here's Why Genmab (GMAB) Looks Ripe for a Turnaround
Genmab (GMAB) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, combined with strong agreement among Wall Street analysts in revising earnings estimates higher, indicates a potential trend reversal for the stock in the near term.
Buy 2 Biotech Bigwigs Set to Gain on Possible Earnings Beat
Two biotech bigwigs set to beat on earnings next week are: ILMN, GMAB.
